Prothena Corp. PLC
Dublin‑based biopharma Prothena builds a multi‑disease pipeline targeting protein dysregulation, with Phase 2 assets like Prasinezumab for synucleinopathies and Coramitug for amyloidosis, supported by Roche and BMS collaborations.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 163
- HQ: Dublin
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.